FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362584098> ?p ?o ?g. }

• W4362584098 endingPage "S205" @default.
• W4362584098 startingPage "S204" @default.
• W4362584098 abstract "PurposeHyperlipidemia has been associated with the development of atherosclerotic cardiovascular disease in non-transplant patients. More recently, first-year LDL cholesterol was found to be a significant risk factor for the development of cardiac allograft vasculopathy (CAV) in a paper by Loupy and colleagues. Previous randomized clinical trials have demonstrated that statins can lower LDL cholesterol as well as decrease the development of CAV. Thus, most heart transplant patients are on statin therapy. In the current era with newer immunosuppressive agents, we sought to confirm that first-year lipid levels have an impact on outcome.MethodsBetween 2010 and 2017 we assessed 260 HTx patients who survived to 1-year, where we assessed first-year lipid levels (where available) to include high vs low levels of total cholesterol (>200 vs <100mg/dl), LDL-cholesterol (>135 vs <70mg/dl), HDL-cholesterol (>60 vs <40mg/dl) and triglycerides levels (>200 vs <150mg/dl). The percent of patients on statin therapy for each group was included. The outcomes included 5-year survival and 5-year freedom from cardiac allograft vasculopathy (CAV: new stenosis ≥30%).ResultsHigh first-year HDL cholesterol levels compared to low levels had significantly greater 5-year survival although there was no significant difference in 5-year freedom from CAV. There was a trend for low LDL-cholesterol levels compared to high levels to have greater freedom from 5-year CAV. There were no significant differences in outcome in high vs low total cholesterol or high vs low triglyceride levels. There were less patients on statins in the high LDL vs low LDL-cholesterol groups. (See Table)ConclusionHTx patients with high HDL may have survival benefit but CAV remains same. Further studies into the reason for this finding are being pursued. Low LDL levels appear to have benefit in 5-year outcome. Hyperlipidemia has been associated with the development of atherosclerotic cardiovascular disease in non-transplant patients. More recently, first-year LDL cholesterol was found to be a significant risk factor for the development of cardiac allograft vasculopathy (CAV) in a paper by Loupy and colleagues. Previous randomized clinical trials have demonstrated that statins can lower LDL cholesterol as well as decrease the development of CAV. Thus, most heart transplant patients are on statin therapy. In the current era with newer immunosuppressive agents, we sought to confirm that first-year lipid levels have an impact on outcome. Between 2010 and 2017 we assessed 260 HTx patients who survived to 1-year, where we assessed first-year lipid levels (where available) to include high vs low levels of total cholesterol (>200 vs <100mg/dl), LDL-cholesterol (>135 vs <70mg/dl), HDL-cholesterol (>60 vs <40mg/dl) and triglycerides levels (>200 vs <150mg/dl). The percent of patients on statin therapy for each group was included. The outcomes included 5-year survival and 5-year freedom from cardiac allograft vasculopathy (CAV: new stenosis ≥30%). High first-year HDL cholesterol levels compared to low levels had significantly greater 5-year survival although there was no significant difference in 5-year freedom from CAV. There was a trend for low LDL-cholesterol levels compared to high levels to have greater freedom from 5-year CAV. There were no significant differences in outcome in high vs low total cholesterol or high vs low triglyceride levels. There were less patients on statins in the high LDL vs low LDL-cholesterol groups. (See Table) HTx patients with high HDL may have survival benefit but CAV remains same. Further studies into the reason for this finding are being pursued. Low LDL levels appear to have benefit in 5-year outcome." @default.
• W4362584098 created "2023-04-06" @default.
• W4362584098 creator A5003637817 @default.
• W4362584098 creator A5026189054 @default.
• W4362584098 creator A5046787475 @default.
• W4362584098 creator A5050616081 @default.
• W4362584098 creator A5050669706 @default.
• W4362584098 creator A5054008185 @default.
• W4362584098 creator A5059998315 @default.
• W4362584098 creator A5070426741 @default.
• W4362584098 creator A5081352490 @default.
• W4362584098 creator A5081500040 @default.
• W4362584098 creator A5091448410 @default.
• W4362584098 date "2023-04-01" @default.
• W4362584098 modified "2023-09-25" @default.
• W4362584098 title "(442) High HDL Levels are Associated with Survival Benefit after Heart Transplantation" @default.
• W4362584098 doi "https://doi.org/10.1016/j.healun.2023.02.457" @default.
• W4362584098 hasPublicationYear "2023" @default.
• W4362584098 type Work @default.
• W4362584098 citedByCount "0" @default.
• W4362584098 crossrefType "journal-article" @default.
• W4362584098 hasAuthorship W4362584098A5003637817 @default.
• W4362584098 hasAuthorship W4362584098A5026189054 @default.
• W4362584098 hasAuthorship W4362584098A5046787475 @default.
• W4362584098 hasAuthorship W4362584098A5050616081 @default.
• W4362584098 hasAuthorship W4362584098A5050669706 @default.
• W4362584098 hasAuthorship W4362584098A5054008185 @default.
• W4362584098 hasAuthorship W4362584098A5059998315 @default.
• W4362584098 hasAuthorship W4362584098A5070426741 @default.
• W4362584098 hasAuthorship W4362584098A5081352490 @default.
• W4362584098 hasAuthorship W4362584098A5081500040 @default.
• W4362584098 hasAuthorship W4362584098A5091448410 @default.
• W4362584098 hasBestOaLocation W43625840981 @default.
• W4362584098 hasConcept C126322002 @default.
• W4362584098 hasConcept C164705383 @default.
• W4362584098 hasConcept C168563851 @default.
• W4362584098 hasConcept C2778163477 @default.
• W4362584098 hasConcept C2778849806 @default.
• W4362584098 hasConcept C2778913445 @default.
• W4362584098 hasConcept C2909963992 @default.
• W4362584098 hasConcept C2911091166 @default.
• W4362584098 hasConcept C71924100 @default.
• W4362584098 hasConcept C90924648 @default.
• W4362584098 hasConceptScore W4362584098C126322002 @default.
• W4362584098 hasConceptScore W4362584098C164705383 @default.
• W4362584098 hasConceptScore W4362584098C168563851 @default.
• W4362584098 hasConceptScore W4362584098C2778163477 @default.
• W4362584098 hasConceptScore W4362584098C2778849806 @default.
• W4362584098 hasConceptScore W4362584098C2778913445 @default.
• W4362584098 hasConceptScore W4362584098C2909963992 @default.
• W4362584098 hasConceptScore W4362584098C2911091166 @default.
• W4362584098 hasConceptScore W4362584098C71924100 @default.
• W4362584098 hasConceptScore W4362584098C90924648 @default.
• W4362584098 hasIssue "4" @default.
• W4362584098 hasLocation W43625840981 @default.
• W4362584098 hasOpenAccess W4362584098 @default.
• W4362584098 hasPrimaryLocation W43625840981 @default.
• W4362584098 hasRelatedWork W1452401547 @default.
• W4362584098 hasRelatedWork W2044741466 @default.
• W4362584098 hasRelatedWork W2068830080 @default.
• W4362584098 hasRelatedWork W2072909849 @default.
• W4362584098 hasRelatedWork W2357470440 @default.
• W4362584098 hasRelatedWork W2383591694 @default.
• W4362584098 hasRelatedWork W2607312240 @default.
• W4362584098 hasRelatedWork W2616599710 @default.
• W4362584098 hasRelatedWork W2794400868 @default.
• W4362584098 hasRelatedWork W2981706002 @default.
• W4362584098 hasVolume "42" @default.
• W4362584098 isParatext "false" @default.
• W4362584098 isRetracted "false" @default.
• W4362584098 workType "article" @default.